ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.884,75
-0,57%
S&P 500
5.930,85
1,09%
Dow Jones
42.840,26
1,18%
Euro vs US Dollar
1,043
0,00%
Bitcoin
95.634,53
-1,62%
Pepperstone
Advertisement
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Design Therapeutics Inc (DSGN)

  7. Design Therapeutics Inc (DSGN) News

DSGN

Design Therapeutics (DSGN)

Design Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:DSGN
DatumZeitQuelleÜberschriftSymbolFirma
20/12/202400h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DSGNDesign Therapeutics Inc
13/11/202414h00GlobeNewswire Inc.Design Therapeutics to Participate in Multiple Upcoming Investor ConferencesNASDAQ:DSGNDesign Therapeutics Inc
07/11/202422h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DSGNDesign Therapeutics Inc
07/11/202422h01GlobeNewswire Inc.Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM PortfolioNASDAQ:DSGNDesign Therapeutics Inc
10/09/202414h00GlobeNewswire Inc.Design Therapeutics to Participate in the 2024 Cantor Global Healthcare ConferenceNASDAQ:DSGNDesign Therapeutics Inc
12/08/202422h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DSGNDesign Therapeutics Inc
09/08/202422h20Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DSGNDesign Therapeutics Inc
05/08/202414h12Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:DSGNDesign Therapeutics Inc
05/08/202414h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DSGNDesign Therapeutics Inc
05/08/202414h00GlobeNewswire Inc.Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ PortfolioNASDAQ:DSGNDesign Therapeutics Inc
17/06/202423h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DSGNDesign Therapeutics Inc
17/06/202423h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DSGNDesign Therapeutics Inc
17/06/202422h12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DSGNDesign Therapeutics Inc
08/05/202422h31Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:DSGNDesign Therapeutics Inc
08/05/202422h09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DSGNDesign Therapeutics Inc
08/05/202422h05GlobeNewswire Inc.Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program MilestonesNASDAQ:DSGNDesign Therapeutics Inc
07/05/202412h30GlobeNewswire Inc.Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare ConferenceNASDAQ:DSGNDesign Therapeutics Inc
19/03/202421h01GlobeNewswire Inc.Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:DSGNDesign Therapeutics Inc
19/03/202412h27IH Market NewsUS Index Futures Decline Ahead of Federal Reserve Meeting, Oil Prices RetreatNASDAQ:DSGNDesign Therapeutics Inc
12/03/202411h30GlobeNewswire Inc.Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio UpdateNASDAQ:DSGNDesign Therapeutics Inc
05/01/202422h41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DSGNDesign Therapeutics Inc
05/01/202422h40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DSGNDesign Therapeutics Inc
06/12/202300h57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DSGNDesign Therapeutics Inc
13/11/202322h14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:DSGNDesign Therapeutics Inc
13/11/202322h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DSGNDesign Therapeutics Inc
13/11/202322h05GlobeNewswire Inc.Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024NASDAQ:DSGNDesign Therapeutics Inc
06/09/202323h13Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:DSGNDesign Therapeutics Inc
31/08/202300h06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DSGNDesign Therapeutics Inc
31/08/202300h02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DSGNDesign Therapeutics Inc
25/08/202323h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DSGNDesign Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:DSGN

Kürzlich von Ihnen besucht

USOTC
BASFY
BASF (QX)
TG
LHA
Deutsche Lufthansa
TG
RHM
Rheinmetall
NYSE
NKE
Nike
NYSE
MRK
Merck
USOTC
ADDYY
Adidas (QX)
TG
MBG
MercedesBenz
AMEX
XLF
Financial Select Sector
COIN
AVAXUSD
Avalanche
NYSE
DIS
Walt Disney
CCOM
SILVER
SILVER
COIN
DOGEUSD
Dogecoin
TG
TUI1
Tui
USOTC
RHHBY
Roche (QX)
TG
BAYN
Bayer
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten